Henry Schein (NASDAQ:HSIC) Announces FY 2026 Earnings Guidance

Henry Schein (NASDAQ:HSIC – Get Free Report) updated its FY 2026 earnings guidance on Monday. The company provided EPS guidance of 5.420-5.480 for the period, compared to the consensus estimate of 5.540. The company issued revenue guidance of $13.8 billion-$13.9 billion, compared to the consensus revenue estimate of $13.8 billion.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. Barrington Research set a $104.00 price objective on Henry Schein in a research report on Wednesday, August 5th. Wall Street Zen upgraded Henry Schein from a “hold” rating to a “buy” rating in a report on Monday, August 17th. Leerink Partners set a $92.00 target price on Henry Schein and gave the stock a “market perform” rating in a research note on Wednesday, October 14th. Morgan Stanley lifted their price target on Henry Schein from $64.00 to $68.00 and gave the stock an “underweight” rating in a report on Tuesday. Finally, Barclays reissued an “overweight” rating and set a $100.00 price target (up from $86.00) on shares of Henry Schein in a research report on Thursday, August 6th. Eight investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Henry Schein currently has an average rating of “Moderate Buy” and a consensus price target of $93.86.

Get Our Latest Analysis on Henry Schein

Henry Schein Trading Down 2.4%

HSIC opened at $82.94 on Wednesday. Henry Schein has a one year low of $68.70 and a one year high of $92.18. The stock has a market capitalization of $9.17 billion, a PE ratio of 22.72, a P/E/G ratio of 1.52 and a beta of 0.87. The business’s 50 day moving average price is $85.70 and its 200 day moving average price is $81.63. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.76 and a current ratio of 1.33.

Henry Schein (NASDAQ:HSIC – Get Free Report) last posted its earnings results on Tuesday, November 3rd. The company reported $1.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.36 by $0.20. Henry Schein had a return on equity of 16.39% and a net margin of 3.07%. The company had revenue of $3.47 billion during the quarter, compared to analysts’ expectations of $3.48 billion. During the same quarter last year, the firm earned $1.38 earnings per share. The firm’s quarterly revenue was up 4.0% compared to the same quarter last year. As a group, equities research analysts expect that Henry Schein will post 5.45 EPS for the current year.

Latest Henry Schein News

These are some of the HSIC news items that stood out recently:

  • Neutral Sentiment: BMO Capital maintained its Hold rating and $85 price target, citing improving dental demand as supportive of recovery but retaining a cautious outlook. Article: Henry Schein: Improving Dental Demand Supports Recovery
  • Neutral Sentiment: Henry Schein presented at the Jefferies Global Healthcare Conference, but the provided reports contain no specific new operating or financial details to assess. Article: Jefferies Global Healthcare Conference transcript
  • Negative Sentiment: The company set 2026 adjusted EPS guidance at $5.42–$5.48, below the roughly $5.54 consensus estimate. Henry Schein attributed the update to a change in non-GAAP financial reporting and recast historical results; its $13.8–$13.9 billion revenue outlook was broadly in line with estimates. The below-consensus profit range may weigh on sentiment, though the reporting change is important context. Article: Henry Schein cuts FY2026 non-GAAP EPS guidance

Henry Schein Company Profile

(Get Free Report)

Henry Schein, Inc. is a global distributor of health care products and services, serving dental and medical practitioners, veterinary professionals, and other health care organizations. The company traces its roots to a pharmacy founded by Henry and Esther Schein in Queens, New York, in 1932. Its offerings include medical and dental supplies, equipment, pharmaceuticals, vaccines, and diagnostic products. Henry Schein also provides practice-management software, technology solutions, and business services designed to help health care professionals manage their operations.

See Also

Earnings History and Estimates for Henry Schein (NASDAQ:HSIC)

Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.